The technology they is referring to uses whole genome sequencing to identify InDel mutations in tumor cells then uses Cas9/gRNA specifc for those InDel sequences to induce double stranded DNA breaks, resulting in cell death. Since those sequences don't in theory exist elsewhere in the patient, it may be safe. Looks like a lot of different gRNAs are needed though for good efficacy.

They use lentivirus and AAVs to deliver them in vivo.

The in vivo efficacy data is...fine. The big thing here is the personalized medicine aspect.

PMID: 35217600